Eagle Pharmaceuticals Issued Four More Patents For Bendeka

Eagle Pharmaceuticals (EGRX) said Tuesday it has been issued four additional patents by the U.S. Patent and Trademark Office related to Bendeka, bringing the total number of patents in the Bendeka family to 14, expiring from 2026 to 2033.

Three of the newly issued patents will be listed in the Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalents Evaluations bringing Eagle’s total Orange Book listed patents for Bendeka to nine.

Bendeka has also received orphan drug designation from the FDA. Eagle continues to pursue obtaining a grant of orphan drug exclusivity which would provide Bendeka exclusivity through December 2022. Bendeka is for the treatment of blood cancer including chronic lymphocytic leukemia and slow-growing non-Hodgkin lymphoma.

By Garrett Hatch